J Korean Med Sci.  2020 Sep;35(38):e337. 10.3346/jkms.2020.35.e337.

Vaccine-related Anaphylaxis Cases Confirmed by KCDC from 2001–2016

• Roh Ej
• Lee MH
• Song KB
• Lee YK
• Kim MK
• Kim TE
• Chung EH

• KMID: 2507097
• DOI: http://doi.org/10.3346/jkms.2020.35.e337

Abstract

Background
A national immunization program (NIP) to prevent disease and reduce mortality from vaccine preventable diseases (VPD) is very important.
Methods
We analyzed only the anaphylaxis cases that occurred between 2001 and 2016 that Korea Centers for Disease Control and Prevention (KCDC) determined had a definite causal relationship with a vaccine. The clinical symptoms were assessed according to the Brighton Collaboration case definition (BCCD) level.
Results
During the period, there were 13 cases of vaccine-related anaphylaxis. The median age was 9 years (range, 1 month to 59 years). The incidence of anaphylaxis per million doses was 0.090 in 2005, 0.079 in 2012, 0.071 in 2013, 0.188 in 2015, and 0.036 in 2016. Of those cases, 23.1% were influenza vaccines, and 76.9% were BCCD level 2. Epinephrine was used in 46.2%.
Conclusion
Vaccine-related anaphylaxis seems to have been very rare in the past, but health care professionals must always be aware of anaphylaxis.

Keyword

Vaccine; Vaccine; Anaphylaxis; Anaphylaxis; Adverse Reaction; Adverse Reaction; Vaccine Preventable Diseases; Vaccine Preventable Diseases

Reference

1. Gold MS, Gidudu J, Erlewyn-Lajeunesse M, Law B. Brighton Collaboration Working Group on Anaphylaxis. Can the Brighton Collaboration case definitions be used to improve the quality of Adverse Event Following Immunization (AEFI) reporting? Anaphylaxis as a case study. Vaccine. 2010; 28(28):4487–4498. PMID: 20434547.

2. Lee JK, Choi WS. Immunization policy in Korea. Infect Chemother. 2008; 40(1):14–23.

3. Kwon YH, Park YJ. The national immunization safety management system in Korea. Public Health Wkly Rep. 2013; 6(25):485–491.

4. Ministry of Health and Welfare, Korea Center for Disease Control & Prevention. Guidelines for Managing Adverse Reactions after Vaccination. Cheongju: Korea Center for Disease Control and Prevention;2011. p. 11–19.

5. Lee DH, Shin SS, Jun BY, Lee JK. National level response to pandemic (H1N1) 2009. J Prev Med Public Health. 2010; 43(2):99–104. PMID: 20383041.

6. Johansson SG, Bieber T, Dahl R, Friedmann PS, Lanier BQ, Lockey RF, et al. Revised nomenclature for allergy for global use: report of the Nomenclature Review Committee of the World Allergy Organization, October 2003. J Allergy Clin Immunol. 2004; 113(5):832–836. PMID: 15131563.

7. Rüggeberg JU, Gold MS, Bayas JM, Blum MD, Bonhoeffer J, Friedlander S, et al. Anaphylaxis: case definition and guidelines for data collection, analysis, and presentation of immunization safety data. Vaccine. 2007; 25(31):5675–5684. PMID: 17448577.

8. Mallory ML, Lindesmith LC, Baric RS. Vaccination-induced herd immunity: successes and challenges. J Allergy Clin Immunol. 2018; 142(1):64–66. PMID: 29803799.

9. Lee J, Jeong H, Kim S, Yu J, Kim G. National childhood vaccination coverage among children aged 1–3 and 6 years in Korea, 2018. Public Health Wkly Rep. 2019; 12(39):1548–1558.

10. McNeil MM, Weintraub ES, Duffy J, Sukumaran L, Jacobsen SJ, Klein NP, et al. Risk of anaphylaxis after vaccination in children and adults. J Allergy Clin Immunol. 2016; 137(3):868–878. PMID: 26452420.

11. Oberle D, Pavel J, Rieck T, Weichert S, Schroten H, Keller-Stanislawski B, et al. Anaphylaxis after immunization of children and adolescents in Germany. Pediatr Infect Dis J. 2016; 35(5):535–541. PMID: 26835973.

12. Lee SY, Ahn K, Kim J, Jang GC, Min TK, Yang HJ, et al. A multicenter retrospective case study of anaphylaxis triggers by age in Korean children. Allergy Asthma Immunol Res. 2016; 8(6):535–540. PMID: 27582405.

13. Yang HJ. Allergic reactions to vaccine components. Allergy Asthma Respir Dis. 2014; 2(3):157–164.

14. Erlewyn-Lajeunesse M, Hunt LP, Heath PT, Finn A. Anaphylaxis as an adverse event following immunisation in the UK and Ireland. Arch Dis Child. 2012; 97(6):487–490. PMID: 22275307.

15. Chung EH. Vaccine allergies. Clin Exp Vaccine Res. 2014; 3(1):50–57. PMID: 24427763.

16. DiMiceli L, Pool V, Kelso JM, Shadomy SV, Iskander J. V.A.E.R.S. Team. Vaccination of yeast sensitive individuals: review of safety data in the US vaccine adverse event reporting system (VAERS). Vaccine. 2006; 24(6):703–707. PMID: 16154669.

17. Oda T, Sawada Y, Okada E, Yamaguchi T, Ohmori S, Haruyama S, et al. Stevens-Johnson syndrome after influenza vaccine injection. J Investig Allergol Clin Immunol. 2017; 27(4):274–275.

18. González-Pérez A, Aponte Z, Vidaurre CF, Rodríguez LA. Anaphylaxis epidemiology in patients with and patients without asthma: a United Kingdom database review. J Allergy Clin Immunol. 2010; 125(5):1098–1104.e1. PMID: 20392483.

19. Clark S, Wei W, Rudders SA, Camargo CA Jr. Risk factors for severe anaphylaxis in patients receiving anaphylaxis treatment in US emergency departments and hospitals. J Allergy Clin Immunol. 2014; 134(5):1125–1130. PMID: 24985399.

20. Iribarren C, Tolstykh IV, Miller MK, Eisner MD. Asthma and the prospective risk of anaphylactic shock and other allergy diagnoses in a large integrated health care delivery system. Ann Allergy Asthma Immunol. 2010; 104(5):371–377. PMID: 20486326.

21. Cheng DR, Perrett KP, Choo S, Danchin M, Buttery JP, Crawford NW. Pediatric anaphylactic adverse events following immunization in Victoria, Australia from 2007 to 2013. Vaccine. 2015; 33(13):1602–1607. PMID: 25698493.

22. Choi YJ, Kim J, Jung JY, Kwon H, Park JW. Underuse of epinephrine for pediatric anaphylaxis victims in the emergency department: a population-based study. Allergy Asthma Immunol Res. 2019; 11(4):529–537. PMID: 31172721.

23. Erlewyn-Lajeunesse M, Brathwaite N, Lucas JS, Warner JO. Recommendations for the administration of influenza vaccine in children allergic to egg. BMJ. 2009; 339:b3680. PMID: 19755545.